Non-Current Liabilities
Total Liabilities
Royalty Pharma Total Liabilities decreased by 0.3% to $9.88B in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 26.3%, from $7.82B to $9.88B. Over 5 years (FY 2020 to FY 2025), Total Liabilities shows an upward trend with a 10.1% CAGR. This is a positive signal — lower values indicate better performance for this metric.
Analysis
StatementBalance Sheet Statement
SectionNon-Current Liabilities
CategoryLeverage
SignalLower is better
VolatilityStable
First reportedQ4 2015
Last reportedQ1 2026
How to read this metric
A rising trend may indicate aggressive expansion or liquidity pressure, while a declining trend suggests deleveraging and improved balance sheet health.
Detailed definition
This represents the aggregate sum of all current and non-current financial obligations owed by the company to external p...
Peer comparison
Used across all industries to assess the overall debt burden relative to equity and assets.
Metric ID:
total_liabilitiesHistorical Data
20 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $6.11B | $7.35B | $7.27B | $7.24B | $7.33B | $7.26B | $7.29B | $7.25B | $7.31B | $6.27B | $6.30B | $6.27B | $7.90B | $7.78B | $7.88B | $7.82B | $8.82B | $9.73B | $9.91B | $9.88B |
| QoQ Change | — | +20.2% | -1.1% | -0.4% | +1.3% | -1.0% | +0.4% | -0.5% | +0.8% | -14.2% | +0.4% | -0.5% | +26.1% | -1.5% | +1.2% | -0.8% | +12.8% | +10.3% | +1.8% | -0.3% |
| YoY Change | — | — | — | — | +20.0% | -1.2% | +0.3% | +0.2% | -0.3% | -13.6% | -13.6% | -13.6% | +8.2% | +24.1% | +25.1% | +24.8% | +11.6% | +25.0% | +25.7% | +26.3% |
Range$6.11B – $9.91B
CAGR+10.6%
Avg YoY Growth+9.3%
Median YoY Growth+9.9%
Total Liabilities at Other Companies
Frequently Asked Questions
- What is Royalty Pharma's total liabilities?
- Royalty Pharma (RPRX) reported total liabilities of $9.88B in Q1 2026.
- How has Royalty Pharma's total liabilities changed year-over-year?
- Royalty Pharma's total liabilities increased by 26.3% year-over-year, from $7.82B to $9.88B.
- What is the long-term trend for Royalty Pharma's total liabilities?
- Over 5 years (2020 to 2025), Royalty Pharma's total liabilities has grown at a 10.1% compound annual growth rate (CAGR), from $6.12B to $9.91B.
- What does total liabilities mean?
- The total amount of money the company owes to all creditors and stakeholders.